PGR and breast cancer: We therefore sought to explore further clinical and demographic differences in order to identify disparities among female patients with luminal (HR+) breast cancer subtypes using Surveillance, Epidemiology, and End Results (SEER) data by assessing estrogen and progesterone receptor status, and the role of SES in risk of disease.